HomePharma

Pharma

Takeda Launches Narcolepsy Drug ORZEYFUL in Japan and China, U.S. Launch Planned

Life Sciences Times - October 15, 2026

Pharma

Takeda Reports Positive Phase 2/3 Results for Experimental Immunodeficiency Treatment

Life Sciences Times - October 14, 2026

Pharma

Calluna Pharma Completes Dosing in Phase 2 Lung Fibrosis Trial, Expects Results in Early 2027

Life Sciences Times - October 13, 2026

Pharma

Alkermes to Present New Narcolepsy and Sleep Disorder Treatment Data at Sleep Europe 2026

Life Sciences Times - October 13, 2026

Pharma

Scholar Rock Resubmits European Application for Spinal Muscular Atrophy Treatment

Life Sciences Times - October 8, 2026

Pharma

Nitto Avecia Records Third Straight FDA Inspection With No Action Indicated

Life Sciences Times - October 7, 2026 0

Pharma

Trinity Report Finds U.S. Drug Launches Outperformed Expectations in 2025

Life Sciences Times - October 5, 2026 0

Pharma

Bayer to Invest $2.2 Billion in New Ohio Pharmaceutical Manufacturing Site

Life Sciences Times - October 5, 2026 0

Pharma

Takeda Says Zasocitinib Outperformed Deucravacitinib in Phase 3 Psoriasis Study

Life Sciences Times - September 30, 2026 0

Pharma

Alnylam Launches ‘Play by Play’ Initiative to Raise Awareness of ATTR-CM

Life Sciences Times - September 29, 2026 0

Pharma

FDA Approves Merck, Eisai Combination for Previously Treated Advanced Kidney Cancer

Life Sciences Times - September 25, 2026 0

Pharma

AstraZeneca’s Imfinzi Combination Gets FDA Priority Review for Muscle-Invasive Bladder Cancer

Life Sciences Times - September 25, 2026 0

Pharma

Acadia Reports Phase 2 Results for Remlifanserin in Alzheimer’s Disease Psychosis

Life Sciences Times - September 24, 2026 0

Pharma

Vertex Reports Positive Phase 2b Results for Inaxaplin in APOL1-Mediated Kidney Disease

Life Sciences Times - September 22, 2026 0

Pharma

Takeda to Present Late-Stage Oncology Data at ESMO 2026

Life Sciences Times - September 22, 2026 0

Pharma

Vertex Partners With Lindsey Vonn to Raise Awareness of Non-Opioid Pain Drug JOURNAVX

Life Sciences Times - September 15, 2026 0

Pharma

Enhertu Improves Progression-Free Survival in HER2-Mutant Lung Cancer Phase 3 Trial

Life Sciences Times - September 14, 2026 0

12 3...101 Page 1 of 101

Perceptive Discovery Expands Radiopharmaceutical Research Capabilities in Massachusetts and UK

October 16, 2026

Boston-Based Clasp Launches Healthcare Job Marketplace Offering Student Loan Repayment Benefits

October 16, 2026

Ironwood Pharmaceuticals Names Tammi Gaskins CEO as Tom McCourt Announces Retirement

October 16, 2026

Estuary Biotherapeutics Launches with $103 Million to Advance Gene Therapies for Kidney Disease

October 16, 2026

Pharma

Takeda Launches Narcolepsy Drug ORZEYFUL in Japan and China, U.S. Launch Planned

Takeda Reports Positive Phase 2/3 Results for Experimental Immunodeficiency Treatment

Calluna Pharma Completes Dosing in Phase 2 Lung Fibrosis Trial, Expects Results in Early 2027

Alkermes to Present New Narcolepsy and Sleep Disorder Treatment Data at Sleep Europe 2026

Scholar Rock Resubmits European Application for Spinal Muscular Atrophy Treatment

Most Read

Perceptive Discovery Expands Radiopharmaceutical Research Capabilities in Massachusetts and UK

Boston-Based Clasp Launches Healthcare Job Marketplace Offering Student Loan Repayment Benefits

Ironwood Pharmaceuticals Names Tammi Gaskins CEO as Tom McCourt Announces Retirement

Estuary Biotherapeutics Launches with $103 Million to Advance Gene Therapies for Kidney Disease

EDITOR PICKS

Acta Pharmaceuticals Raises $24 Million to Advance Alzheimer’s Disease Treatments

Akamis Bio Completes Enrollment in Phase 1b Rectal Cancer Treatment Study

Mursla Bio Publishes Study Validating Tissue-Specific Liquid Biopsy Technology

THIS WEEK'S STORIES

Butterfly Network Partners With VCOM to Expand Ultrasound Training for Medical Students

Takeda Launches Narcolepsy Drug ORZEYFUL in Japan and China, U.S. Launch Planned

Myomo Names Mary-Katherine McClure Chief Commercial Officer

POPULAR CATEGORY

ABOUT US

FOLLOW US